Notifications
Back

POLYTAXEL®

A next-generation anticancer therapy


 POLYTAXEL®

A next-generation anticancer therapy

First-line Cancer Treatment

Polymer-Based Low-Toxicity First-Line Anticancer Therapy

POLYTAXEL®, often referred to as a “pain-free” anticancer therapy, is a novel formulation in which docetaxel—a widely used chemotherapeutic agent—is incorporated into an advanced Polymer-Based Drug Delivery System (DDS). 

POLYTAXEL®, often referred to as a “pain-free” anticancer therapy, is a novel formulation in which docetaxel—a widely used chemotherapeutic agent—is incorporated into an advanced Polymer-Based Drug Delivery System (DDS). 

POLYTAXEL® Structure

Component 
Role
Application / Characteristics
Docetaxel
Drug
A chemotherapeutic agent
Aconiticacid
Linker
Naturally occurring substance in the body
Lysine
Spacer
Essential amino acid
Poly
(phosphazene)
Backbone
Applied in humans (U.S., Europe)
MPEG 550
Solubilizing
Widely used in drug delivery systems

POLYTAXEL®
Key Features

POLYTAXEL® overcomes the limitations of conventional chemotherapies by enabling a significantly higher maximum tolerated dose (NOAEL). It delivers optimized efficacy by safely targeting cancer cells with minimal concerns about side effects. 

* No Observed Adverse Effect Level

Key Features 01

Slow Release
01

Gradual degradation in the body allows controlled and sustained drug release. 

Key Features 02

Tumor Targeting
02

Through the EPR effect, it selectively accumulates in tumor tissues after passing through normal tissues. 

Key Features 03

Low Toxicity
03

Minimizes systemic drug exposure, significantly reducing toxicity and side effects compared to conventional therapies. 

Comparison of Actual Dose vs NOAEL

Compared to conventional chemotherapies, toxicity is significantly reduced, while the allowable dosing range is greatly expanded— offering a next-generation anticancer solution with enhanced therapeutic potential. 

Docetaxel

Due to its low NOAEL, conventional 
cytotoxic chemotherapy requires 
doses exceeding the safe threshold 
to achieve efficacy. 


 POLYTAXEL®

Compared to docetaxel, 
Polytaxel significantly increases 
the safe dosing range (up to ~44×). 


A New Paradigm in Cancer Treatment

A new therapeutic paradigm that minimizes toxicity while maintaining efficacy through a NOAEL-based dosing strategy.

Metronomic Therapy


Repeated low-dose administration precisely controls systemic toxicity. 

Suppresses tumor growth rather than directly eliminating tumors, helping preserve the patient’s immune system. 

Requires frequent dosing, which may increase patient burden. 

NOAEL Therapy


Prioritizes patient safety and tolerability while minimizing toxicity. 

Induces effective tumor cell death. 

Applies long-circulation technology to maintain therapeutic levels while reducing dosing frequency. 

Preserves the patient’s immune system throughout treatment. 

MTD Therapy


High-dose administration aims for aggressive tumor reduction at the maximum tolerable level. 

Increased risk of toxicity and side effects due to high-dose exposure. 

May damage normal cells and weaken the immune system, potentially leading to resistance. 

First-line Cancer Treatment

Polymer-Based Low-Toxicity First-Line Anticancer Therapy 

POLYTAXEL®, often referred to as a “pain-free” anticancer therapy, is a novel formulation in which docetaxel—a widely used chemotherapeutic agent—is incorporated into an advanced Polymer-Based Drug Delivery System (DDS). 

It is engineered at an ultra-small nanoparticle size of approximately 10 nm to enable effective delivery even to hard-to-reach organs such as the pancreas. To further enhance delivery efficiency to major organs, poorly water-soluble docetaxel has been reformulated into a water-soluble form, improving its bioavailability and distribution

POLYTAXEL® Structure

Component 
Role
Application / Characteristics 
Docetaxel
Drug
A chemotherapeutic agent 
Aconiticacid
Linker
Naturally occurring 
substance in the body
Lysine
Spacer
Essential amino acid
Poly(phosphazene)
Backbone
Applied in humans 
(U.S., Europe)
MPEG 550
Solubilizing
Widely used in 
drug delivery systems 

POLYTAXEL® Key Features

POLYTAXEL® overcomes the limitations of conventional chemotherapies by enabling 
a significantly higher maximum tolerated dose (NOAEL). It delivers optimized efficacy by 
safely targeting cancer cells with minimal concerns about side effects. 

* No Observed Adverse Effect Level 


Key Features 01

Slow Release
01

Gradual degradation in the body allows controlled and sustained drug release. 



Key Features 02

Tumor Targeting
02

Through the EPR effect, it selectively accumulates in tumor tissues after passing through normal tissues. 


Key Features 03

Low Toxicity
03

Minimizes systemic drug exposure, significantly reducing toxicity and side effects compared to conventional therapies. 

Comparison of Actual Dose vs NOAEL

Compared to conventional chemotherapies, toxicity is significantly reduced,
while the allowable dosing range is greatly expanded— offering 
a next-generation anticancer solution with enhanced therapeutic potential. 

Docetaxel

Due to its low NOAEL, conventional cytotoxic chemotherapy 
requires doses exceeding the safe threshold to achieve efficacy. 


 POLYTAXEL®

Compared to docetaxel, Polytaxel significantly 
increases the safe dosing range (up to ~44×). 


A New Paradigm in 
Cancer Treatment

A new therapeutic paradigm that minimizes toxicity 
while maintaining efficacy through a NOAEL-based dosing strategy. 

Metronomic Therapy


Repeated low-dose administration precisely controls systemic toxicity. 

Suppresses tumor growth rather than directly eliminating tumors, helping preserve the patient’s immune system. 

Requires frequent dosing, which may increase patient burden. 

NOAEL Therapy


Prioritizes patient safety and tolerability while minimizing toxicity. 

Induces effective tumor cell death. 

Applies long-circulation technology to maintain therapeutic levels while reducing dosing frequency. 

Preserves the patient’s immune system throughout treatment. 

MTD Therapy


High-dose administration aims for aggressive tumor reduction at the maximum tolerable level. 

Increased risk of toxicity and side effects due to high-dose exposure. 

May damage normal cells and weaken the immune system, potentially leading to resistance. 

CEO geunwoo jin
Email contact@hyundaibio.com
Tel 1544-3194    |    Fax 053-756-4055

Address  Hyundai Bioscience Co., Ltd., 8th Floor, Botanic Gate, 166, Magokdong-ro, Gangseo-gu, Seoul, 07790, Korea

PR Site

Family Sites

Copyright ⓒ 2026 HYUNDAI BIOSCIENCE All rights reserved.

CEO geunwoo jin    |    Email contact@hyundaibio.com     |    Tel 1544-3194    |    Fax 053-756-4055

Address  Hyundai Bioscience Co., Ltd., 8th Floor, Botanic Gate, 166, Magokdong-ro, Gangseo-gu, Seoul, 07790, Korea

Copyright ⓒ 2026 HYUNDAI BIOSCIENCE All rights reserved.

PR Site

Family Sites